FDA plans to eye "corrective" DTC

Share this article:

FDA has outlined plans to study the use of corrective DTC TV ads as a way of remedying deceptive advertising. The agency wants to know how exposure to a combination of original and corrective ads affects message recall, message comprehension, perceived efficacy and risk and intent to ask a doctor about the drug. It also wants to find out how comprehension might relate to theme and visual elements in the advertisements as well as to the length of delay between the original ad and the corrective ad.

The agency plans to conduct 6,650 online interviews for the study. Ads will feature fake products for asthma and weight loss.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro